{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:09:40Z","timestamp":1764266980051,"version":"3.46.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00125-024-06314-1","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T21:03:08Z","timestamp":1730926988000},"page":"249-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-8523","authenticated-orcid":false,"given":"Aikaterini","family":"Eleftheriadou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-6524","authenticated-orcid":false,"given":"David","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7353","authenticated-orcid":false,"given":"Sizheng S.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8855-220X","authenticated-orcid":false,"given":"Philip","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-455X","authenticated-orcid":false,"given":"Gema","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-1555","authenticated-orcid":false,"given":"Timothy L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-8404","authenticated-orcid":false,"given":"John P. H.","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-1122","authenticated-orcid":false,"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"6314_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06300-7","author":"Y-H Tsai","year":"2024","unstructured":"Tsai Y-H, Hemphill NO, Kurth T (2024) Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-024-06300-7","journal-title":"Diabetologia"},{"issue":"7","key":"6314_CR2","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","volume":"67","author":"A Eleftheriadou","year":"2024","unstructured":"Eleftheriadou A, Riley D, Zhao SS et al (2024) Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia 67(7):1271\u20131282. https:\/\/doi.org\/10.1007\/s00125-024-06132-5","journal-title":"Diabetologia"},{"issue":"3","key":"6314_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","volume":"19","author":"D Li","year":"2017","unstructured":"Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H (2017) Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 19(3):348\u2013355. https:\/\/doi.org\/10.1111\/dom.12825","journal-title":"Diabetes Obes Metab"},{"key":"6314_CR4","unstructured":"National Institute for Health and Care Excellence (2023) Obesity: identification, assessment and management. Available from: www.nice.org.uk\/guidance\/cg189. Accessed: 14 October 2024"},{"issue":"Supplement_1","key":"6314_CR5","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee (2023) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024. Diabetes Care 47(Supplement_1):S158\u2013S178. https:\/\/doi.org\/10.2337\/dc24-S009","journal-title":"Diabetes Care"},{"key":"6314_CR6","doi-asserted-by":"publisher","first-page":"e078225","DOI":"10.1136\/bmj-2023-078225","volume":"385","author":"B Pasternak","year":"2024","unstructured":"Pasternak B, Wintzell V, Hviid A et al (2024) Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ 385:e078225. https:\/\/doi.org\/10.1136\/bmj-2023-078225","journal-title":"BMJ"},{"key":"6314_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3233\/SHTI230070","volume":"302","author":"A Mu\u00f1oz Monjas","year":"2023","unstructured":"Mu\u00f1oz Monjas A, Rubio Ruiz D, P\u00e9rez-Rey D, Palchuk M (2023) Automatic outlier detection in laboratory result distributions within a real world data network. Stud Health Technol Inform 302:88\u201392. https:\/\/doi.org\/10.3233\/SHTI230070","journal-title":"Stud Health Technol Inform"},{"issue":"4","key":"6314_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1055\/a-2130-2197","volume":"14","author":"L Evans","year":"2023","unstructured":"Evans L, London JW, Palchuk MB (2023) The detection of date shifting in real-world data. Appl Clin Inform 14(4):763\u2013771. https:\/\/doi.org\/10.1055\/a-2130-2197","journal-title":"Appl Clin Inform"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06314-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-024-06314-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06314-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:07:54Z","timestamp":1764266874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-024-06314-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6314"],"URL":"https:\/\/doi.org\/10.1007\/s00125-024-06314-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"type":"print","value":"0012-186X"},{"type":"electronic","value":"1432-0428"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PA and GH are employees of TriNetX. UA has received honoraria from Viatris, Gr\u00fcnenthal, Eli Lilly, Procter & Gamble for educational meetings, and has received investigator-led funding form Proctor & Gamble. UA has received sponsorship for educational meetings from Daiichi Sankyo and Sanofi. GYHL is a speaker for BMS\/Pfizer, Boehringer Ingelheim, Daiichi Sankyo and Anthem. No fees are received personally. He is also a co-principal investigator of the AFFIRMO project on multi-morbidity in atrial fibrillation, which has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement no. 899871. TLJ is a consultant to 2CTech, Alcon, Dutch Ophthalmic Research Centre, iLumen, Opthea, Outlook Therapeutics, Oxurion, Pfizer, Regeneron and Voiant. He has received conference support from Roche. He receives free equipment use for non-commercial trials from Zeiss, Oraya and LKC. His employer receives site payments for participants on commercial clinical trials of various eye conditions including diabetic retinopathy. JPHW reports: consultancy\/advisory board work for the pharmaceutical industry contracted via the University of Liverpool (no personal payment) for Altimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Cytoki, Lilly, Napp, Novo Nordisk, Menarini, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern and Shionogi; research grants for clinical trials from AstraZeneca and Novo Nordisk; and personal honoraria\/lecture fees from AstraZeneca, Boehringer Ingelheim, Medscape, Napp, Novo Nordisk and Rhythm. JPHW is the past president of the World Obesity Federation, and a member of the Association for the Study of Obesity, Diabetes UK, EASD, ADA, Society for Endocrinology and the Rank Prize Funds Nutrition Committee. From 2009\u20132024 he was national lead for the Metabolic and Endocrine Speciality Group of the UK NIHR Clinical Research Network. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"AE drafted and UA revised the response. All authors reviewed the final text, provided input and agreed to its publication. All authors approved the version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}